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Introduction {#sec1}
============

*Ras* small GTPases are key regulators of multiple signaling cascades, controlling diverse cellular processes ([@bib9], [@bib37]). Ras activity depends on its two forms through binding partners: active GTP-bound and inactive GDP-bound Ras ([@bib3]). Around 30% of different types of human cancers contain mutant Ras genes (K-Ras, H-Ras, N-Ras) with persistently activated GTP-bound state ([@bib2]), which results in constitutively activated RAS signaling even in the absence of extracellular stimuli. Oncogenic Ras signaling has been implicated in malignant transformation of cancers ([@bib2], [@bib34]). The frequency of *Ras* mutations varies greatly among cancer types, with very low frequency detected in some tumors such as esophageal squamous cell carcinoma (ESCC) ([@bib6], [@bib14]), nasopharyngeal carcinoma (NPC) ([@bib24], [@bib25]), and breast cancer ([@bib5], [@bib40]). However, even in the absence of Ras mutations, aberrant activation of Ras signaling is still common and critical for these tumors.

A family of Ras GTPase-activating proteins (RasGAPs) stimulates the GTPase activity of wild-type RAS but not its oncogenic mutants and turns activated Ras GTP-bound state into its inactive GDP-bound state ([@bib3], [@bib21]). RasGAPs inactivate RAS signaling and inhibit oncogenic transformation initiated by RAS. RasGAP family comprises of diverse proteins with different expression patterns in normal development and diseases. So far, 14 RasGAPs have been identified in mammals ([@bib15]), with tumor-suppressive functions, and epigenetic alterations have been documented for several RasGAPs in various cancer types ([@bib27]), including *NF1* ([@bib8]), *DAB2IP* ([@bib10]), *RASAL1* ([@bib20]), and *RASAL2* ([@bib28]). Thus, alternative mechanisms like inactivation of negative regulators of Ras signaling might have contributed to uncontrolled Ras signaling in cancers with infrequent Ras mutations.

Among RasGAPs, the RASA subfamily consists of five RasGAPs ([@bib27]): RASA1/p120GAP, three GAP1 members (RASA2/GAP1m, RASA3/GAP1IP4BP, and RASA4/CAPRI), and RASA5/SynGAP. The RASA group, as negative regulators of Ras signaling, could act as tumor suppressors in cancer pathogenesis. *RASA1* inactivating mutations, as driver mutation, defines a genetically novel subclass of non-small cell lung cancer, together with *NF1* mutations ([@bib16], [@bib22]). Allelic loss of *RASA1* is frequent in triple-negative breast cancer with TP53 mutations, and its downregulation leads to the malignant phenotype of mammary cells ([@bib39]). *RASA2* inactivating mutations, as a melanoma driver, are associated with patient's poor survival ([@bib1]). *RASA3* was identified as a functional tumor suppressor in gastric and colon cancers ([@bib38]). *RASA4* hypermethylation is correlated with patient's poor prognosis in resistant juvenile myelomonocytic leukemia ([@bib33]).

In this study, we report our identification and characterization of RASA5 as a tumor-suppressive RasGAP for human cancers. We defined a hemizygous 6p21.3 microdeletion in carcinomas by array comparative genomic hybridization and identified *RASA5* as a disrupted target at this deletion. *RASA5* was originally identified as a brain-specific RasGAP modulating synaptic transmission and plasticity ([@bib7], [@bib23]). Despite its known role in neuronal development, its pathogenic role, especially in tumorigenesis, has never been studied. We found that *RASA5* was broadly expressed in multiple normal tissues, albeit at lower levels than brain tissue. We further investigated its tumor-suppressive functions in antagonizing Ras signaling in tumor cells. Our study elucidates the importance of epigenetic disruption of RASA5 as a RasGAP to drive aberrant Ras signaling activation in human cancers, especially those with infrequent Ras mutations.

Results {#sec2}
=======

*RASA5* as a Downregulated Target at the Identified 6p21.3 Deletion and Associated with Poor Clinical Outcome {#sec2.1}
-------------------------------------------------------------------------------------------------------------

We detected a hemizygous microdeletion at 6p21.3 in carcinoma cell lines by 1-Mb array-CGH analysis ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Chromosomal regions with genetic loss likely harbor candidate tumor suppressor genes (TSGs). We thus further examined expression levels of 23 genes localized within this deletion by semi-quantitative reverse transcription (RT)-PCR in a panel of tumor cell lines (3x NPC, 4x ESCC, 2x CRC, and 1x NSCLC), with normal tissues (testis, larynx, and esophagus) as controls. Significant downregulation of *RASA5* was detected in all cell lines, with downregulation of *LEMD2* and *IP6K3* also seen in some cell lines ([Figure S1](#mmc1){ref-type="supplementary-material"}B and [Table S1](#mmc1){ref-type="supplementary-material"}), suggesting that *RASA5* is the major candidate TSG within this deletion with its downregulation related to tumorigenesis.

*RASA5* expression was previously reported to be brain specific by traditional Northern blot assay. To further examine its expression pattern, we examined its expression at both mRNA and protein levels in multiple normal tissues. Results showed variable but ubiquitous expression of *RASA5* RNA in human normal tissues, *albeit* most abundantly in the brain when fewer PCR cycles were used ([Figure 1](#fig1){ref-type="fig"}A). We also accessed the GeneCards database and identified basal-level expression of *RASA5* in human tissues ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Furthermore, endogenous expression of RASA5 protein (\~148 kDa) was detected in normal esophageal, trachea, breast, and testis tissues by Western blot, with the highest level in brain as expected ([Figures 1](#fig1){ref-type="fig"}B and [S2](#mmc1){ref-type="supplementary-material"}). Immunohistochemistry (IHC) staining (Human Protein Atlas cohort) also showed RASA5 protein expression in most normal tissues, ranging from high to low levels, and located in the cell cytoplasm ([Figures 1](#fig1){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}B). These results suggest that RASA5 is a brain-dominant but not brain-restricted protein, likely possessing important functions in other normal tissues as well.Figure 1*RASA5* Is Expressed in Multiple Normal Tissues including Brain but Downregulated in Carcinomas(A) Examination of *RASA5* transcript in normal tissues by semi-quantitative RT-PCR, using different PCR cycles (28, 26, and 24 cycles), with *GAPDH* as a control. PBMC, peripheral blood mononuclear cells.(B) RASA5 protein expression in normal tissues detected by Western blot, with brain tissue as the highest level. Anti-RASA5 antibody (Ab1, ThermoFisher, PA1-046) was used, with β-actin as a loading control (upper panel). Graph represents quantification of Western blots with fold change (lower panel). Data were presented as mean ± SEM of three independent experiments and representative data were shown.(C) IHC of normal tissue microarrays (esophagus, nasopharynx, breast) from Human Protein Atlas ([www.proteinatlas.org](http://www.proteinatlas.org){#intref0025}, version 17). Anti-RASA5/SYNGAP1 pAb (HPA038373, Sigma-Aldrich) was used at a 1:35 ratio for staining.(D) Box plots showing *RASA5* mRNA expression levels between ESCC and normal esophagus tissues, normal breast, and breast neoplasm with different stages (Oncomine datasets). The number of samples (n) and p values (determined by two-tailed Student\'s t test and Mann-Whitney U test) were shown.(E) Kaplan-Meier curve showing overall survival of patients with HNSCC (The Cancer Genome Atlas) (log rank p = 2.80 × 10^−4^) or breast cancer (RMSPC) (log rank p = 0.033).(F) Somatic mutations of *RASA5* and *RASA1* genes in human cancers (<https://cancer.sanger.ac.uk/cosmic>).

Further bioinformatic analysis of the Oncomine database confirmed *RASA5* downregulation in ESCC and breast tumor clinical samples, with significant reduction observed in benign breast neoplasm and breast tumor samples ([Figure 1](#fig1){ref-type="fig"}D). We also performed Kaplan-Meier meta-analyses to analyze the clinical significance of *RASA5* deregulation in tumors using online databases (Protein Atlas version 18, bc-GenExMiner v4.1). *RASA5* low expression was significantly associated with poor outcome of patients with head and neck squamous cell carcinoma (HNSCC) and breast cancer ([Figure 1](#fig1){ref-type="fig"}E), suggesting an important role of *RASA5* disruption in tumorigenesis.

*RASA5* Expression Is Repressed by Promoter CpG Methylation in Human Cancers {#sec2.2}
----------------------------------------------------------------------------

Loss-of-function mutations of RASA members such as RASA1 are well documented in human cancers; we thus investigated possible genetic alterations of *RASA5* in cancers using the COSMIC tumor database. Surprisingly, only \<2% of cases (upper aero-digestive track, esophagus, lung, and breast) had detectable *RASA5* mutations, compared with its high-frequent (\~8%) mutations in nerve system cancer ([Figure 1](#fig1){ref-type="fig"}F). Thus, genetic mutation of *RASA5* is not common in human cancers.

Downregulation or loss of *RASA5* was detected in multiple tumor cell lines but not immortalized normal cell lines ([Figures 2](#fig2){ref-type="fig"}A, 2B, [S2](#mmc1){ref-type="supplementary-material"}C, and [S3](#mmc1){ref-type="supplementary-material"}A and [Table S2](#mmc1){ref-type="supplementary-material"}). Interestingly, in direct contrast to cancer-associated downregulation of *RASA5*, other RASA family members (*RASA1*, *2*, *3*, and *4*) were broadly expressed and only occasionally silenced in tumor cell lines ([Figures 2](#fig2){ref-type="fig"}C and [S3](#mmc1){ref-type="supplementary-material"}B), indicating that *RASA5* has unique and important functions in tumorigenesis among the RASA family.Figure 2Promoter CpG Methylation Mediates *RASA5* Downregulation in Cancers(A) RASA5 expression and methylation analyzed in carcinomas with fewer Ras mutations. *RASA5* expression levels determined by semi-quantitative RT-PCR. NPC, nasopharyngeal carcinoma; ESCC, esophageal squamous cell carcinoma. Ca, cancer. *RASA5* promoter methylation was analyzed by methylation-specific PCR (MSP). M, methylated; U, unmethylated.(B) Western blot of RASA5 expression in representative tumor cell lines. Anti-RASA5 antibody (Ab1, ThermoFisher) was used, with GAPDH as a loading control. Graph represents quantification of Western blots with fold change (right). Data were presented as mean ± SEM of three independent experiments and representative data were shown.(C) Expression of other RASA family members (*RASA1, 2, 3*, and *4*) in ESCC and NPC cell lines as detected by semi-quantitative RT-PCR.(D) *RASA5* promoter CpG island, CpG sites shown as short vertical lines, methylation-specific PCR (MSP) primers, and bisulfite genomic sequencing (BGS) region indicated. BGS was used to examine *RASA5* methylation in tumor cells. Every row of circles represented an individual promoter allele clone sequenced. Filled circles indicated methylated CpG sites, whereas empty ones unmethylated sites. Cell lines treated with demethylating agent Aza (A), combined with or without Trichostatin A (T). Genetic demethylation of colorectal cell line HCT116 with double knockout of DNMT1 and DNMT3B (DKO).(E) Pharmacologic and genetic demethylation reactivated *RASA5* expression in carcinoma cell lines. Aza (A), Trichostatin A (T). Genetic demethylation of HCT116 with knockout (KO) of DNMT1 (1KO) or DNMT3B (3BKO) or both (DKO) also rescued *RASA5* expression and demethylated the promoter, with complete demethylation in DKO.(F) *RASA5* methylation in tumor samples of ESCC, NPC, and breast cancers and adjacent nonmalignant (A) or normal tissues. T, tumor; N, normal.(G) Inverse correlation between *RASA5* expression and promoter methylation in esophageal and breast cancers through analyzing TCGA cohorts. Each blue circle represents a single clinical sample. Spearman correlation coefficient analysis was used.(H) Association of *RASA5* methylation with overall survival was analyzed in esophageal and breast invasive tumor samples from TCGA datasets. Ca, cancer. The Kaplan-Meier estimator was used.

Further analysis using CpG Island Searcher (<http://cpgislands.usc.edu/>) identified a CpG island spanning *RASA5* transcription start site and exon 1, suggesting possible *RASA5* silencing by promoter CpG methylation ([Figure 2](#fig2){ref-type="fig"}D). We thus performed methylation-specific PCR (MSP) to examine *RASA5* promoter methylation and its correlation with expression levels. Results showed that cell lines with reduced or loss of *RASA5* expression were frequently methylated in the promoter ([Figures 2](#fig2){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}A). *RASA5* is methylated in all ESCC and NPC cell lines (18m/18 and 5m/5, respectively) and 67% (6m/9) breast cancer cell lines but not methylated in any corresponding immortalized normal epithelial cell lines ([Figures 2](#fig2){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}C and [Table S2](#mmc1){ref-type="supplementary-material"}). To validate the MSP results, we employed high-resolution methylation analysis using bisulfite genomic sequencing (BGS) to analyze the methylation status of 13 CpG sites within *RASA5* CGI. The BGS results are consistent with MSP data ([Figure 2](#fig2){ref-type="fig"}D).

Next, to establish the causal relationship between *RASA5* silencing and its promoter methylation, we performed pharmacologic demethylation of *RASA5*-silenced cell lines. We treated cells (HCT116, KYSE150, MB231) with demethylating agent 5-aza-2′-deoxycytidine (5-Aza) together with or without histone deacetylase inhibitor Trichostatin A (TSA). *RASA5* RNA expression and methylation after treatment were assayed by semi-quantitative RT-PCR and MSP. Dramatic upregulation of *RASA5* expression was observed in all of the examined cell lines upon drug treatment, accompanied by increased unmethylated promoter alleles and decreased methylated alleles ([Figure 2](#fig2){ref-type="fig"}E). Genetic demethylation of a colon cancer cell line (HCT116) by knockout (KO) of either single DNMT1 (1KO cell line) or DNMT3B (3BKO cell line) restored *RASA5* expression through abolishing methylation, and knockout of both DNMT1 and DNMT3B (DKO cell line) achieved highest *RASA5* expression level and more unmethylated alleles ([Figure 2](#fig2){ref-type="fig"}E). Further high-resolution BGS analysis confirmed the pharmacologic and genetic demethylation of *RASA5* promoter ([Figure 2](#fig2){ref-type="fig"}D). These results indicate that promoter methylation plays a critical and direct role in *RASA5* silencing in human tumor cells.

Promoter Methylation of *RASA5* Is Common in Multiple Primary Tumors {#sec2.3}
--------------------------------------------------------------------

We further examined the methylation status of *RASA5* promoter in multiple primary tumors and adjacent nonmalignant tissues. *RASA5* methylation was detected in 35% (24m/69) of ESCC tumors (including 20 paired samples), whereas only two paired surgically marginal nonmalignant tissues showed weak methylation and no normal esophagus tissue had methylation detected ([Figures 2](#fig2){ref-type="fig"}F and [S3](#mmc1){ref-type="supplementary-material"}C). Moreover, *RASA5* promoter methylation was detected frequently in other tumor samples, including 82% (18m/22) of NPC, 68% (13m/19) of breast, 73% (8m/11) of colon, and 62% (32m/52) of gastric tumors ([Figures 2](#fig2){ref-type="fig"}F, [S3](#mmc1){ref-type="supplementary-material"}D, and S3E and [Table S2](#mmc1){ref-type="supplementary-material"}), in direct contrast to the absence of methylation in normal tissues. Detailed BGS analysis further confirmed the dense methylation of *RASA5* promoter alleles in representative primary tumors but not normal tissues ([Figure S3](#mmc1){ref-type="supplementary-material"}F).

We retrieved *RASA5* methylation and mRNA expression data from 183 esophageal and 656 breast invasive cancer samples in The Cancer Genome Atlas database. Linear regression analysis revealed an inverse correlation between *RASA5* promoter methylation and its mRNA expression in esophageal and breast cancer patients ([Figure 2](#fig2){ref-type="fig"}G). Moreover, esophageal and breast invasive cancer patients with lower methylation of *RASA5* are associated with better overall survival ([Figure 2](#fig2){ref-type="fig"}H). These results suggest that *RASA5* promoter methylation is tumor-specific and responsible for its downregulation/silencing in primary tumors.

RASA5 Functions as a Tumor Suppressor in Multiple Carcinoma Cells {#sec2.4}
-----------------------------------------------------------------

We next investigated the tumor biology function of RASA5 in cancer cells. Ectopic expression of RASA5 in methylated and silenced tumor cell lines (KYSE150, HNE1, and MB231) dramatically reduced their colony formation abilities to 17%-50% (\*p \< 0.05) together with decreased colony sizes, compared with control cells transfected with empty vectors ([Figures 3](#fig3){ref-type="fig"}A and 3B), indicating that RASA5 functions as a TSG in carcinoma cells.Figure 3RASA5 Functions as a Tumor Suppressor in Carcinoma Cells(A) Representative colony formation assay by monolayer culture of *RASA5*-expressing ESCC, NPC, and breast tumor cells. Quantitative analyses of colony numbers shown as values of mean ± SEM of three independent experiments using Student\'s t test (lower panel), with colonies (\>50 cells) in empty vector-transfected cells set as 100; \*, p \< 0.05.(B) *RASA5* expression was confirmed using both anti-Flag and anti-RASA5 (Ab1, ThermoFisher) by Western blot. The straight arrow represents the specific band of RASA5 detected by anti-Flag antibody. Graphs represent quantification of Western blots with fold change compared with controls (lower panel). Data were presented as mean ± SEM of three independent experiments via Student\'s t test. \*\*\*, p \< 0.001.(C) Characteristic nuclear changes of apoptotic cells after *RASA5* expression. Arrows indicate EGFP+ cells.(D) Cleavage of apoptotic markers, PARP and caspase-3, in carcinoma cells transfected with Flag-tagged RASA5 construct. GAPDH served as a loading control. Graphs represent quantification of Western blots with fold change compared with controls (right). \*\*, p \< 0.01; \*\*\*, p \< 0.001. Data were presented as mean ± SEM of three independent experiments via Student\'s t test.(E) Xenograft tumor formation of MB231 carcinoma cells expressing *RASA5* or vector only. Cells were injected subcutaneously into nude mice. Representative photographs of H&E staining of xenografts (200x, 400x magnification).(F) Horizontal bars show mean tumor weight and volume. Statistically significant decrease in tumor weight and growth (\*\*, p \< 0.01) upon ectopic *RASA5* expression was observed. Data were presented as mean ± SEM of three independent experiments via Student\'s t test.

We also assessed the role of RASA5 on tumor cell apoptosis. Chromatin condensation and nuclei rupture as hallmarks of apoptotic cells were observed in EGFP-*RASA5* transfected KYSE150 and HNE1 carcinoma cells with DAPI staining, whereas the nuclei of vector control cells remained intact ([Figure 3](#fig3){ref-type="fig"}C). Western blot assays confirmed that RASA5 enhanced the protein levels of apoptotic markers including cleaved poly (ADP-ribose) polymerase (PARP) and cleaved caspase-3 ([Figure 3](#fig3){ref-type="fig"}D). We also examined the effect of RASA5 on caspase-3 cleavage and activation using an apoptosis reporter system. The caspase3-sensor protein can be translocated into cell nuclei, then show stronger fluorescence when caspase-3\'s nuclear exclusion sequence is cleaved off and activated upon cell apoptosis. We observed many more carcinoma cells showing activated nuclei-localized caspase-3 after RASA5 expression than controls transfected with empty vectors ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B), indicating that RASA5 expression could induce carcinoma cell apoptosis.

To study RASA5 functions further *in vivo*, *RASA5*- and empty vector-transfected MB231 cells were injected subcutaneously into nude mice to generate xenograft tumor models. Results showed that tumor weight and sizes of RASA5-expressing xenografts were significantly decreased compared with controls ([Figures 3](#fig3){ref-type="fig"}E and 3F). These results provide direct evidence that RASA5 indeed functions as a TSG in carcinoma cells.

RASA5 Inhibits Carcinogenesis through Antagonizing RAS Signaling {#sec2.5}
----------------------------------------------------------------

Further analysis of cancer genomic database (<http://www.cbioportal.org/>) showed that *RASA5* inactivating mutations appear to be mutually exclusive to the active mutations of *KRAS*, *HRAS,* and *NRAS* in ESCC, NPC, and breast tumors, although in general genetic mutations of these genes are rare in these carcinomas ([Figure 4](#fig4){ref-type="fig"}A). A similar trend was also observed in HNSCC tumors, which had a relatively higher *HRAS* mutation rate (\~6%) ([Figure 4](#fig4){ref-type="fig"}A).Figure 4RASA5 Is Partially Co-localized with ER/Golgi and Actin Tails in Carcinoma Cells(A) *RASA5* mutations in cancer databases (<http://www.cbioportal.org/>), together with KRAS, HRAS, and NRAS mutations.(B) RASA5 subcellular localization stained by indirect immunofluorescence. Exogenous expression of RASA5 was examined by anti-Flag antibody (green) in COS7 and KYSE150 cells. Endogenous expression of RASA5 in BT549 and T47D cells was examined by two different anti-RASA5 antibodies (Ab1, ThermoFisher; Ab2, Epitomics, green), nuclei counterstained with DAPI (blue). Original magnification, 400x. Scale bar 200 μM.(C) Co-localization of RASA5 with ER/Golgi compartments and actin tails. KYSE150 cells were co-transfected with Flag-RASA5 plasmid and either ER- or Golgi-specific plasmid (pDsRed-ER and pEYFP-Golgi, respectively). BT549 cells were transfected with ER- or Golgi-specific plasmid, respectively. Nuclei counterstained with DAPI (blue). Original magnification, 400x. Scale bar 200 μM.(D) Promoter activities of SRE reporter were evaluated in RASA5-expressing cells by dual-luciferase assay, normalized to values of Renilla luciferase activity. Results were expressed as fold reduction of activity and shown as mean ± SEM of three independent experiments performed in triplicate analyzed by Student\'s t test. Bottom panel: SRE-Luc reporter activity was reduced in KYSE150 cells with a RASA5 dosage-dependent manner; \*, p \< 0.05.

RASA5 protein showed cytoplasmic subcellular localization with a punctuated distribution pattern in exogenously expressed COS7 and KYSE150 cells, as well as endogenously expressed BT549 and T47D cells, partially Golgi and/or endoplasmic reticulum(ER)-located ([Figure 4](#fig4){ref-type="fig"}B). This was further confirmed by co-localization of RASA5 with ER/Golgi compartment, as assayed with ER- or Golgi-specific fluorescent plasmid transfection (pDsRed-ER and pEYFP-Golgi, respectively) in RASA5 exogenously and endogenously expressed cells. Results showed that RASA5 signal was partially overlapped with that of ER (red) or Golgi (green) ([Figure 4](#fig4){ref-type="fig"}C). Moreover, some RASA5 proteins were obviously localized at the tips of actin tails in carcinoma cells ([Figure 4](#fig4){ref-type="fig"}C), whereas actin tail formation and retraction has been reported critically involved in cell migration.

We examined the effect of RASA5 on RAS signaling using luciferase reporters of SRE-Luc, AP-1-Luc, and TOPFlash for screening RASA5 downstream effectors. Results showed that ectopic expression of RASA5 significantly downregulated activities of SRE-Luc, AP-1-Luc, and TOPFlash in both HEK293 and KYSE150 cell lines ([Figures 4](#fig4){ref-type="fig"}D and [S4](#mmc1){ref-type="supplementary-material"}C) and suppressed SRE-Luc reporter activities in a dosage-dependent manner ([Figure 4](#fig4){ref-type="fig"}D). We further examined effects of RASA5 on downstream MAPK/ERK and AKT signaling cascades by Western blot. Results showed dramatically reduced phosphorylation levels of key effectors of MAPK/ERK signaling (p-MEK1/2, p-ERK1/2) and AKT signaling (p-AKT) in RAS wild-type KYSE150 and HNE1 cells, as well as KRAS G13D-mutated MB231 cells ([Figure 5](#fig5){ref-type="fig"}A). Ras activity assay also showed substantially reduced amount of active GTP-bound Ras in RASA5-expressing tumor cells ([Figure 5](#fig5){ref-type="fig"}B). Moreover, introduction of oncogenic HRAS Q61L mutant abolished the suppression effects by RASA5 reconstitution on MAPK/ERK and AKT signaling effectors, through upregulating RAS-GTP activity ([Figures 5](#fig5){ref-type="fig"}A and 5B).Figure 5RASA5 Functions as a RasGAP and Antagonizes RAS Signaling(A) Western blot of phosphor-MEK (pMEK), phosphor-ERK (pERK), and phosphor-Akt (pAKT) following RASA5 expression in RAS-wild-type (wt) KYSE150 and HNE1 cells, as well as KRAS-mutant (mut) MB231 cells. Ectopic expression of RASA5 downregulated phosphorylation levels of RAS signaling effectors, whereas active RAS mutant form (HRAS Q61L) counteracted this suppression. GAPDH used as a control. Quantification of the phosphor-immunoblots normalized to corresponding total protein levels (right). Data were presented as mean ± SEM of three independent experiments via Student\'s t test and representative data were shown. \*, p \< 0.05; \*\*, p \< 0.01; \*\*\*, p \< 0.001.(B) Active GTP-bound form of Ras was pulled down by Raf-RBD and subjected to Western blot analysis. RASA5 downregulated Ras-GTP level, but overexpression of oncogenic HRAS Q61L reversed this suppression. Graph represents quantification of Western blots with fold change compared with controls (right). Data were presented as mean ± SEM of three independent experiments via Student\'s t test and representative data were shown. \*\*\*, p \< 0.001.(C) Semi-quantitative RT-PCR analyses of RASA5 inhibitory effect on Ras target oncogenes *MCL1* and *c-MYC* at mRNA levels. Ectopic expression of HRAS Q61L mutant abrogated this inhibition. wt, wild-type; mut, mutant.

In addition, given that nuclear translocation was essential for activated ERK1/2 to exert its transcriptional regulations, the subcellular localization of ERK1/2 in cells with or without RASA5 re-expression was assessed. Results showed that RASA5 restoration in HONE1 cells markedly repressed the nuclear aggregation of phosphor-ERK1/2 ([Figure S4](#mmc1){ref-type="supplementary-material"}D), which was also confirmed on the other hand by knockdown of endogenous RASA5 in carcinoma cells resulting in nuclear aggregation of phosphor-ERK1/2 ([Figure S4](#mmc1){ref-type="supplementary-material"}E). Meanwhile, RASA5 caused reduction in expression levels of RAS target oncogenes *MCL1* and *c-MYC* RNA, which could be reversed by ectopic expression of constitutively active HRAS Q61L mutant ([Figure 5](#fig5){ref-type="fig"}C).

The constitutively active HRAS Q61L mutant could rescue the suppression effect (to 40%--80%) of RASA5 over carcinoma cells in both anchorage-independent and -dependent growth, through monolayer colony and soft agar formation assays ([Figures 6](#fig6){ref-type="fig"}A and 6B). Furthermore, knockdown of endogenous RASA5 by two different siRNAs significantly increased colony formation abilities of T47D and BT549 cells ([Figure 6](#fig6){ref-type="fig"}C), consistent with the enhanced ERK phosphorylation levels ([Figures 6](#fig6){ref-type="fig"}D and [S5](#mmc1){ref-type="supplementary-material"}). Treatment of specific MEK inhibitors (PD98059 and U0126) showed significant inhibition of phosphorylated ERK levels, but not its total protein levels, in cells with or without RASA5 knockdown ([Figures 6](#fig6){ref-type="fig"}D and [S5](#mmc1){ref-type="supplementary-material"}). Treatment of MEK inhibitors also led to decreased tumor cell colony numbers and sizes. However, further knockdown of *RASA5* in treated cells still slightly increased their colony numbers ([Figure 6](#fig6){ref-type="fig"}C). Collectively, these results demonstrate that RASA5 acts as a Ras-GAP to inhibit carcinoma cell proliferation through negatively regulating RAS signaling.Figure 6RASA5 Acts as a Tumor Suppressor via Its Effects on Ras Signaling(A and B) Inhibition of anchorage-independent and -dependent growth by RASA5 in the presence of concomitantly expressed HRAS Q61L Ras-mutant in KYSE150 and HNE1 cells, by monolayer (A) and soft agar (B) colony formation assays. HNE1 and KYSE150 cells were transfected with vector or RASA5-expressing plasmid and selected with G418 at appropriate concentrations. Quantitative analyses of colony numbers are shown as values of mean ± SEM of three independent experiments using Student\'s t test, with colonies (\>50 cells) in empty vector-transfected cells set as 100; \*\*, p \< 0.01; \*\*\*, p \< 0.001.(C) Monolayer culture assay of T47D and BT549 cells were treated with two different RASA5 siRNAs (siRNA-1, Invitrogen; siRNA-2, Origene), with or without the treatment with MEK inhibitors (20 μM PD98059 or 10 μM U0126). Each bar represents mean ± SEM for three independent experiments via Student\'s t test, with colonies (\>50 cells) in empty vector-transfected cells set as 100. \*, p \< 0.05; \*\*, p \< 0.01; \*\*\*, p \< 0.001.(D) Western blot analysis of ERK1/2 phosphorylation in *RASA5* knocked-down T47D and BT549 cells treated with DMSO or MEK inhibitors PD98059 (20 μM) or U0126 (10 μM) for 2 hours. All experiments were repeated three times and representative data were shown.

The RasGAP Domain Is Functionally Indispensable for RASA5 Activity {#sec2.6}
------------------------------------------------------------------

The human *RASA5* encodes a 1343 amino acid (aa) protein, structurally consisting of 3 functional domains: an N-terminal PH (pleckstrin homology) (aa 27-253), a C2 domain (aa 263-365), and a GAP domain (aa 392-729). Protein sequence alignment of RASA5 from different species by ClustalX indicates that the RASA5 protein is evolutionarily well conserved ([Figure S6](#mmc1){ref-type="supplementary-material"}). We generated three truncated variants, RASA5^ΔGAP−G\ (aa\ 392−729)^, RASA5^ΔGAP−L\ (aa\ 373−1343)^, and RASA5^ΔC2−GAP\ (aa\ 259−1343)^, with deletion of GAP domain or GAP and C2-GAP domains, to analyze the importance of these domains in RASA5 functions toward Ras activity regulation ([Figure 7](#fig7){ref-type="fig"}A).Figure 7RASA5 Exerts Its Tumor Suppressive Function Dependent on its GAP Domain(A) Schematic view of full-length RASA5 (wild type) and three truncated mutants (RASA5^ΔGAP−G^, RASA5^ΔGAP−L^, RASA5^ΔC2−GAP^). ΔGAP-G: RASA5 with only RasGAP domain deleted; ΔGAP-L: RASA5 with PH and C2 domains remained; ΔC2-GAP: RASA5 with C2 and RasGAP domains deleted.(B and E) Representative immunofluorescence analysis of subcellular localization of wild-type RASA5 and truncated mutants, RASA5^ΔGAP−L^ and RASA5^ΔC2−GAP^ mutants (B); RASA5^ΔGAP−G^ mutant (E), labeled with anti-Flag antibody (green) or anti-RASA5 (Ab1, ThermoFisher). Nuclei marked by DAPI (blue). Original magnification, 400x. Scale bar 200 μM.(C and F) Effects of deletions of GAP domain and C2-GAP tandem on cell growth by colony formation assay. KYSE150 cells transiently transfected with plasmid expressing RASA5 or either of the three mutants, RASA5^ΔGAP−L^ and RASA5^ΔC2−GAP^ mutants (C); RASA5^ΔGAP−G^ mutant (F). Number of colonies was presented in a bar graph (data were mean ± SEM of three independent experiments, \*, p \< 0.05; \*\*, p \< 0.01; \*\*\*, p \< 0.001). Data were presented as mean ± SEM of three independent experiments by One Way ANOVA with multiple comparison post hoc analysis and representative data were shown.(D and G) Western blot of phosphorylation of ERK1/2 and AKT in tumor cells with expression of RASA5 or three truncated mutants. (D) Effects of RASA5 and two indicated RASA5 mutants on ERK1/2 and AKT phosphorylation in KYSE150 cells. (G) Phosphorylation of ERK1/2 and AKT in KYSE150 and MB231 cells with expression of RASA5 and RASA5^ΔGAP−G^ mutant. Graphs represent quantification of the phosphor-immunoblots normalized to corresponding total protein levels (lower panel). Data were presented as mean ± SEM of three independent experiments by One Way ANOVA with multiple comparison post hoc analysis and representative data were shown. \*, p \< 0.05; \*\*, p \< 0.01; \*\*\*, p \< 0.001.

We first evaluated the effect of these domains in the subcellular localization of RASA5. Result showed altered diffused nuclear localization of RASA5^ΔGAPs\ (−G,\ −L)^ and RASA5^ΔC2−GAP^ mutants compared with the cytoplasmic distribution of wild-type RASA5, whereas the RASA5^ΔGAP−G^ mutant still partially retained cytoplasmic distribution ([Figures 7](#fig7){ref-type="fig"}B and 7E). The impact of these mutants on cell growth was also examined by clonogenic assay. The inhibition effect of colony formation by wild-type RASA5 was variably lost in cells expressing RASA5^ΔGAPs\ (−G,\ −L)^ or RASA5^ΔC2−GAP^ mutant ([Figures 7](#fig7){ref-type="fig"}C and 7F). We next analyzed their effects on Ras activation by examining the phosphorylation levels of ERK1/2 and AKT. Both RASA5^ΔGAPs\ (−G,\ −L)^ and RASA5^ΔC2−GAP^ mutants failed to suppress the phosphorylation of ERK1/2 and AKT, compared with wild-type RASA5 ([Figures 7](#fig7){ref-type="fig"}D and 7G). Together, our results suggest the RasGAP domain is functionally indispensable for the catalytic activity of RASA5.

RASA5 Inhibits Carcinoma Cell Migration and Invasion through Epithelial-Mesenchymal Transition (EMT) {#sec2.7}
----------------------------------------------------------------------------------------------------

To fully characterize the oncogenic effect of RASA5 disruption, we assessed whether RASA5 might suppress carcinoma cell migration and invasion by wound healing or invasion assay. Scratch wound was made on confluent cell monolayer and observed 24 h later and cells transfected with empty vector got wound closed, where RASA5-expressing carcinoma cells remained unhealed ([Figure S7](#mmc1){ref-type="supplementary-material"}A). Moreover, matrigel invasion assay showed much fewer RASA5-expressing tumor cells invaded through the membrane into lower chamber than controls ([Figure 8](#fig8){ref-type="fig"}A). These results suggest that RASA5 is able to suppress carcinoma cell migratory and invasion.Figure 8RASA5 Restoration Suppresses Tumor Cell Invasion and Reverses Cell EMT Phenotype(A) Matrigel invasion chamber assay of RASA5-expressing MB231 cells. Invaded cells at the lower surface of transwell filter were stained and counted. \*, p \< 0.05. Scale bar 200 μM. Each bar represented mean ± SEM of three independent experiments with control cells as the baseline using Student\'s t test.(B) Morphology changes of HNE1 and MB231 cells stably expressing RASA5. Original magnification, 400x. Scale bar 200 μM.(C) Ectopic RASA5 expression upregulated E-cadherin, downregulated vimentin, fibronectin and phosphorylation levels of Rac, cofilin, and JNK1/2 by Western blot in HNE1 and MB231 cells. GADPH as a loading control. Graphs represent quantification of Western blots with fold changes compared with controls (right). Data were presented as mean ± SEM of three independent experiments via Student\'s t test and representative data were shown. \*, p \< 0.05; \*\*, p \< 0.01; \*\*\*, p \< 0.001.(D) Expression of EMT markers (E-cadherin, vimentin, and fibronectin) was examined by Western blot in BT549 and T47D cells with RASA5-knockdown through two different siRNAs (siRASA5-1, siRASA5-2). Right panel graphs represent quantification of Western blots with fold changes compared with controls (right). \*, p \< 0.05; \*\*, p \< 0.01. Data were presented as mean ± SEM of three independent experiments via Student\'s t test and representative data were shown.

As EMT is important in cancer cell migration and invasion, we next examined the influence of EMT by RASA5 expression. The morphology of HNE1 and MB231 carcinoma cells changed from spindle-shaped mesenchymal cell to cobblestone-like epithelial cell type following the restoration of RASA5 ([Figure 8](#fig8){ref-type="fig"}B). On the other hand, RASA5-depleted T47D carcinoma cells by siRNA knockdown showed morphologic conversion from epithelial cell to mesenchymal cell-like ([Figure S7](#mmc1){ref-type="supplementary-material"}B). Further epithelial or mesenchymal markers were examined as molecular indicators of the impact of RASA5 on carcinoma cell EMT. Ectopic expression of RASA5 upregulated epithelial marker E-cadherin and downregulated mesenchymal markers vimentin and fibronectin by Western Blot and immunofluorescence assays ([Figures 8](#fig8){ref-type="fig"}C and [9](#fig9){ref-type="fig"}A). Conversely, knockdown of RASA5 in carcinoma cells led to upregulated fibronectin and vimentin but deceased E-cadherin expression ([Figure 8](#fig8){ref-type="fig"}D).Figure 9RASA5 Restoration Reversed Cell EMT Phenotype in Carcinoma Cells(A) Immunofluorescence labeling of EMT markers (fibronectin and vimentin) in HNE1 and MB231 cells with RASA5 re-expression. Cells transiently transfected with RASA5-EGFP construct or empty vector. Arrows indicate EGFP+ cells. Original magnification, 400x. Scale bar 200 μM.(B) Immunofluorescence analysis of actin cytoskeletal protein F-actin in RASA5-expressing cells. HNE1 cells expressing RASA5 were round in shape and mostly lacked a clearly defined leading edge protrusion of F-actin that vector-transfected cells usually showed (arrows). Proper F-actin stress fibers formed in control cells after stress treatment, while impaired in RASA5-expressing MB231 cells by rhodamine-labeled phalloidin staining. Original magnification, 400x. Scale bar 200 μM.(C) Representative stem cell markers detected by semi-quantitative RT-PCR in HNE1, KYSE150, and MB231 cells with stable expression of RASA5, along with or without concomitantly expressed active RAS mutant form (HRAS Q61L).(D) Proposed model of alternative mechanism of activating Ras signaling via deregulation of RasGAP protein RASA5 during human carcinogenesis. Loss of RASA5 is detected in multiple carcinomas and tightly correlated with promoter CpG methylation. RASA5 restoration inhibits carcinoma cell growth and metastasis through inhibiting Ras signaling.

EMT is fundamentally linked to actin cytoskeleton reorganization; we further examined the impact of RASA5 on cytoskeletal reorganization. Carcinoma cells normally are with F-actin--accumulated leading edge (actin tails) for cell migration direction. However, carcinoma cells with RASA5 expression exhibited alterations in cell shape from polarized to roundish and lost the clearly defined leading edge protrusion ([Figure 9](#fig9){ref-type="fig"}B). Immunofluorescence staining with rhodamine-labeled phalloidin further showed that actin stress fibers formed in control cells after starvation treatment, whereas disassembled in RASA5-expressing cells ([Figures 9](#fig9){ref-type="fig"}B and [S7](#mmc1){ref-type="supplementary-material"}C). RASA5 proteins appeared in some actin tail tips and thin, membranous tubes connecting COS-7 cells, highly similar to the tunneling nanotubes for actin-based cytoplasmic extensions ([Figure S7](#mmc1){ref-type="supplementary-material"}D). Accordingly, phosphorylation of cofilin, a terminal effector of actin cytoskeletal rearrangement, was downregulated in RASA5-expressing cells, together with its upstream signaling molecules p-JNK and p-Rac ([Figure 8](#fig8){ref-type="fig"}C).

As EMT promotes invasiveness and stem cell-like features (stemness) of cancer cells, we extended our study to investigate whether RASA5 could affect carcinoma cell stemness. The expression of classic stem cell markers, including *NANOG*, *NESTIN*, *OCT4*, *KLF4, CD44,* and *ABCG2*, was downregulated in RASA5-expressing cells by semi-quantitative RT-PCR, whereas HRAS Q61L active mutant counteracted this inhibition effect ([Figure 9](#fig9){ref-type="fig"}C), suggesting that RASA5 regulates EMT/MET plasticity in carcinoma and in turn affects actin cytoskeleton reorganization, cell migration/invasion, and cell stemness.

Discussion {#sec3}
==========

In this study, we demonstrate an alternative mechanism of abnormally activating wild-type RAS signaling in carcinoma cells through epigenetic disruption of a RasGAP. We identified a RasGAP member, RASA5, epigenetically silenced in a tumor-specific manner in multiple carcinomas. Gain-of-function assay revealed that RASA5 expression was apoptotic to carcinoma cells and led to the inhibition of their growth, migration, and invasion through regulating EMT, actin cytoskeleton reorganization, and cell stemness. RASA5 was shown to exert tumor-suppressive functions through downregulating Ras-GTP level and further attenuating RAS signaling. These inhibitory effects could be abrogated in the presence of active RAS mutant or by deletion of RasGAP domain of RASA5. Furthermore, loss-of-function assay showed RAS activation, enhancement of carcinoma cell growth, and EMT upon loss of RASA5. These results demonstrate a causal role of RASA5 silencing in aberrant RAS activation during human carcinogenesis. This demonstrates a tumor suppressive role of RASA5 in Ras signaling perturbation in carcinomas, in addition to its classic role in neuronal development.

Loss of negative regulators of RAS signaling by genetic or epigenetic alterations may be a common oncogenic driver in human cancers. Since our group and others previously first reported the frequent epigenetic disruption of a RasGAP member, RASAL/RASAL1, as a functional TSG in multiple tumors ([@bib4], [@bib20], [@bib26], [@bib30]), other RasGAP members have also been identified as TSGs epigenetically inactivated, including *RASAL2* ([@bib13], [@bib17], [@bib28], [@bib31]), *DAB2IP* ([@bib11], [@bib12], [@bib29]), and *NF1* ([@bib8], [@bib35]), highlighting the important contribution of epigenetic mechanism inactivating RasGAP members. Although only rare mutations of *RASA5* were detected in human cancers, we identified a predominant role of promoter methylation accounting for *RASA5* inactivation. We found that *RASA5* was frequently downregulated in multiple human cancers with or without RAS mutations. Another important finding of this study is that, apart from its important role in neuronal/brain development and function, we found that RASA5 actually is broadly expressed across human normal tissues, albeit at lower and variable expression levels, and likely involved in the carcinogenesis of multiple carcinomas.

RASA5 belongs to SynGAP subfamily that structurally consists of an N-terminal PH domain, a C2 domain, and a GAP domain at the C-terminus. RASA5 has been shown to be a negative regulator of Ras regulating neuronal MAPK/ERK signaling in cultured neurons ([@bib36]). Consistent with previous studies, we confirmed the GAP activity of RASA5 to RAS in carcinoma cells. Moreover, our assays using truncation mutants deficient of GAP domain or C2-GAP tandem demonstrated that the catalyzing activity of GAP domain is a functional prerequisite for RASA5. Meanwhile, we found that the C2 domain might also have some impact on GAP activity of RASA5, as RASA5^ΔC2−GAP^ seemed to affect RASA5 subcellular localization, Ras activation, and cell growth, at a slighter grade, when compared with RASA5^ΔGAPs\ (−G,\ −L)^.

RasGAPs are supposed to be potential tumor suppressors owing to their capabilities to maintain RAS proteins in inactive GDP-bound state ([@bib21], [@bib27]). RASA5 mutant mice died in the first postnatal week, indicating the importance of RASA5 for normal development, although the exact cause of death remained unclear ([@bib19], [@bib32]). Here we demonstrated that ectopic expression of RASA5 in RASA5-deficient carcinoma cells decreased the levels of active GTP-bound Ras, whereas knockdown of endogenous RASA5 increased the levels of active form. Accordingly, by overexpression or knockdown of RASA5 in carcinoma cells, RASA5 was shown with multifaceted tumor suppressor functions involving cell growth, EMT, stemness, and migration/invasion. A mechanistic explanation for the constitutively activated states of oncogenic Ras mutant proteins was the loss of negative feedback regulation by RasGAPs. In agreement with this, we found a functional deficiency of RASA5 to wide-type RAS in that RASA5 failed to decrease the levels of GTP-bound Ras in carcinoma cells with ectopic expression of constitutively active oncogenic HRAS Q61L mutant. However, similar inhibitory effect was still observed in carcinoma cells with endogenous mutant K-RAS ([Figures 5](#fig5){ref-type="fig"} and [7](#fig7){ref-type="fig"}), which might be due to the presence of other intact wild-type RAS genes in the cell lines. Therefore, our data suggest that RASA5 can serve as a negative regulator of wild-type RAS signaling and exert its tumor suppressor role in human cancers with wild-type Ras ([Figure 9](#fig9){ref-type="fig"}D).

In summary, our findings broadened the current understanding of the biological function of RASA5, from normal neuronal development to carcinogenesis, which could act as a tumor suppressor in cancers with wild-type *Ras* through inhibition of Ras activity and downstream signaling pathways. We further highlighted the important role of epigenetic silencing of RasGAPs in Ras-mediated carcinogenesis, further in line with our previous findings of RASAL/RASAL1 involvement in multiple tumorigenesis. Restoration of RASA5 activity through pharmacologic intervention might be further exploited as a therapeutic strategy.

Limitation of the Study {#sec3.1}
-----------------------

In this study, we identified a 6p21.3 gene *RASA5/SYNGAP1* antagonizing aberrant Ras signaling in human cancers, which was previously recognized as a RasGAP related to neural cell development and regulation. As *RASA5* is frequently silenced by promoter CpG methylation in human cancers, unlike other RASA family members, further investigation of its tumor suppressive roles in other human cancers with more Ras mutations is needed. In addition to Ras signaling, whether other cross-talking signaling pathways may also be regulated by RASA5 during tumorigenesis should be studied more. RASA5 exerts significant suppression to EMT and stemness in tumor cells; in-depth mechanic study for its regulation of the self-renewal of cancer stem-like cells is also needed.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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